By Allie Nawrat and By Chris Lo 27 Nov 2019
Regulatory breaches at drug manufacturing sites in India and China have fuelled concerns over the safety of the API supply chain and sparked calls for countries to repatriate production of critical medicines. But is this a good idea? Two writers explore the pros and cons of taking back control of API manufacturing.
Regulatory breaches at drug manufacturing sites in India and China have fuelled concerns over the safety of the API supply chain and sparked calls for countries to repatriate production of critical medicines. Credit: Shutterstock.